Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocular Therapeutix reports strong Q4 performance and eyes pivotal trials

Ocular Therapeutix delivered a strong performance in Q4 2022, showcasing revenue growth and advancements in key product developments.
While facing financial challenges and the need for strategic partnerships, the company's solid cash position and product pipeline offer opportunities for future growth.
Investors should monitor Ocular Therapeutix's progress in pivotal trials, commercial expansion, and potential alliances to assess its long-term growth prospects.

Ocular Therapeutix progresses on OTX-TKI program and boosts sales

Ocular Therapeutix showcased advancements in its OTX-TKI program and DEXTENZA sales growth, while addressing financial performance.
Positive clinical trial updates and pricing strategy enhancements position the company for future growth.
Challenges include lack of operational spend guidance and uncertainties in study timelines, with opportunities in trial outcomes and market expansion.

Ocular Therapeutix reports record revenue, navigates pivotal trial funding

Ocular Therapeutix (OCUL) achieved record revenue with DEXTENZA and made significant progress in pipeline development.
While facing financial challenges and operational complexities, the company's strategic initiatives and leadership additions position it for future growth.
Advancements in trial designs, FDA interactions, and funding strategies offer avenues for enhancing product development and commercialization.

Ocular Therapeutix reports strong Q3 revenue growth and advances AMD treatment

Ocular Therapeutix's Q3 performance reflects revenue growth driven by DEXTENZA, with a focus on advancing wet AMD treatment through the OTX-TKI program.
While facing challenges in R&D expenses and trial enrollment criteria, the company is well-positioned with funding options and strategic partnerships.
Opportunities lie in expanding DEXTENZA's market presence, achieving pipeline milestones, and leveraging funding avenues for future growth and innovation.

Ocular Therapeutix excels in retinal focus, poised for leadership

Ocular Therapeutix is on a positive trajectory with advancements in key studies and a strong financial position. The company faces competition and regulatory challenges but has the potential to lead in retinal disease treatment with its innovative approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average of price targets set by Wall Street analysts indicates a potential upside of 64.6% in Ocular Therapeutix (OCUL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade

FAT Brands

Ocular Therapeutix and Fat Brands have solid growth and momentum in SA Quant Factor Grades with potentially high upside in line with consensus price targets. Ocular Therapeutix is up over 50% in the past 30 days and has 15%+ sales growth YoY. The stock has almost 80% upside potential according to sell-side analyst targets. Fat Brands is up 20% in the past year, with forward EBIT growth at ~260% and upside of more than 100% according to consensus price targets.

2 Solid Quant-Rated Growth Stocks With High Consensus Upside Potential (SA Quant)

SHANGHAI , Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health Sciences Authority (HSA) has accepted its New Drug Application (NDA) for DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. DEXTENZA is approved in the U.S. and listed in Macau for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti

Strategic promotion underscores commitment to commercial growth across Ocular portfolio Strategic promotion underscores commitment to commercial growth across Ocular portfolio

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-related macular degeneration using AXPAXLI, its axitinib intravitreal implant; First patient to be dosed Q1 of 2024. Patient compliance with ocular disorder treatment could be improved. The hope is that the company's extended-release hydrogel technology Elutyx can greatly reduce the need for frequent injections.

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

The consensus price target hints at a 134.8% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?

SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company's pivotal Phase 3 SOL clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Ocular Therapeutix (OCUL) Stock Might be a Great Pick

Larimar Therapeutics Inc

Biotech could be poised to rebound in 2024. Wall Street thinks clinical and early commercial-stage drugmakers may be among the group's best performers this year.

Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

Dollar Tree

Globalstar

Intercorp Financial Services Inc

Occidental Petroleum

Verrica Pharmaceuticals Inc

Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.

Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying

BEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the closing of its previously announced underwritten public offering of 35,420,000 shares of its common stock at a public offering price of $3.25 per share, which includes 4,620,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions. The total gross proceeds of the public offering were approximately $115.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the shares in the offering were sold by the Company.

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 4,620,000 shares in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about December 18, 2023, subject to the satisfaction of customary closing conditions.

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by the Company. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President and CEO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Peter Kaiser - Chief Medical Advisor, Retina Conference Call Participants Jon Wolleben - JMP Yi Chen - H.C. Wainwright Operator Good day.

Ocular Therapeutix, Inc. (OCUL) Q3 2023 Earnings Call Transcript

FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

SHANGHAI , Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery. The trial met its primary endpoint, with Dextenza demonstrating a significant reduction of ocular inflammation as measured by the absence of anterior chamber cells (i.e.

AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

Expected to Enroll Approximately 300 Evaluable Subjects Primarily in the United States Expected to Enroll Approximately 300 Evaluable Subjects Primarily in the United States

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

BeiGene

Bristol-Myers

Kezar Life Sciences Inc

Novartis

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at 11:00 AM EDT.

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2023 Earnings Call Transcript August 7, 2023 4:30 PM ET Company Participants Antony Mattessich - President & CEO Donald Notman - CFO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Conference Call Participants Dane Leone - RJF Jon Wolleben - JMP Joe Catanzaro - Piper Sandler Colleen Kusy - Baird Kelly Shi - Jefferies Tara Bancroft - TD Cowen Chaitanya G - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by.

Ocular Therapeutix, Inc. (OCUL) Q2 2023 Earnings Call Transcript

DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; Cash Runway Now Forecasted into 2025 First of Two Planned Pivotal Clinical Trials for OTX-TKI in Wet AMD Expected to Initiate in Q3 2023 Completed Enrollment of HELIOS U.S.-based OTX-TKI Phase 1 Clinical Trial for Treatment of Non-Proliferative Diabetic Retinopathy; 6-Month Interim Data Anticipated Q1 2024 Completed Enrollment of OTX-TIC Phase 2 Clinical Trial and Began Pilot Repeat-Dose Sub-Study BEDFORD, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter ended June 30, 2023, and provided updates on its ophthalmology pipeline.

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period

News for Ocular Therapeutix Stock (OCUL)